Stock listing
OTC:CYDY CytoDyn Inc. Stock
Follow CytoDyn Inc. into a list and get an email when it puts out news.
Share price · OTC:CYDY
$0.222 USD -0.003 (-1.3%)
Close on Nov 20, 2026
- Day range
- $0.221 – $0.237 USDNov 20, 2026
- Volume
- 796,019 sharesNov 20, 2026
- Market cap
- $326.4M USDAt the close on Nov 20, 2026 · price × 1.47B shares outstanding
- 52-week range
- $0.180 – $0.400 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $362,336 USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:CYDY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.222 | -0.003 | -1.3% | $0.230 | $0.237 | $0.221 | 796,019 | |
| $0.225 | -0.024 | -9.8% | $0.250 | $0.255 | $0.225 | 2,831,055 | |
| $0.250 | -0.001 | -0.3% | $0.259 | $0.259 | $0.242 | 1,174,321 | |
| $0.250 | +0.000 | +0.1% | $0.250 | $0.265 | $0.246 | 1,012,918 | |
| $0.250 | +0.015 | +6.2% | $0.241 | $0.253 | $0.240 | 976,731 | |
| $0.235 | +0.004 | +1.5% | $0.235 | $0.250 | $0.232 | 862,483 | |
| $0.232 | -0.001 | -0.5% | $0.240 | $0.245 | $0.226 | 564,529 | |
| $0.233 | -0.007 | -2.9% | $0.232 | $0.240 | $0.230 | 673,552 | |
| $0.240 | +0.010 | +4.4% | $0.230 | $0.240 | $0.227 | 541,175 | |
| $0.230 | +0.004 | +1.8% | $0.238 | $0.240 | $0.225 | 655,946 | |
| $0.226 | -0.003 | -1.2% | $0.222 | $0.230 | $0.220 | 510,083 | |
| $0.229 | +0.002 | +1.0% | $0.225 | $0.229 | $0.220 | 240,706 | |
| $0.226 | +0.006 | +2.8% | $0.221 | $0.235 | $0.221 | 709,237 | |
| $0.220 | +0.000 | 0.0% | $0.243 | $0.243 | $0.220 | 284,148 | |
| $0.220 | -0.005 | -2.2% | $0.225 | $0.230 | $0.217 | 386,293 | |
| $0.225 | +0.013 | +6.1% | $0.217 | $0.228 | $0.212 | 463,617 | |
| $0.212 | -0.006 | -2.6% | $0.220 | $0.225 | $0.212 | 1,303,483 | |
| $0.218 | -0.018 | -7.8% | $0.237 | $0.240 | $0.215 | 2,132,595 | |
| $0.236 | -0.024 | -9.2% | $0.257 | $0.282 | $0.236 | 2,753,371 | |
| $0.260 | +0.020 | +8.3% | $0.240 | $0.277 | $0.235 | 2,141,127 | |
| $0.240 | -0.010 | -4.0% | $0.250 | $0.250 | $0.240 | 2,401,300 | |
| $0.250 | 0.000 | 0.0% | $0.250 | $0.260 | $0.240 | 2,489,000 | |
| $0.250 | 0.000 | 0.0% | $0.270 | $0.290 | $0.240 | 7,348,600 | |
| $0.250 | +0.020 | +8.7% | $0.230 | $0.290 | $0.230 | 6,377,900 | |
| $0.230 | +0.020 | +9.5% | $0.210 | $0.230 | $0.210 | 3,962,300 | |
| $0.210 | +0.010 | +5.0% | $0.200 | $0.210 | $0.200 | 3,277,400 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.210 | $0.200 | 991,600 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.210 | $0.200 | 627,000 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.210 | $0.200 | 1,172,200 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.200 | $0.200 | 1,981,900 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.200 | $0.200 | 1,778,000 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.200 | $0.200 | 1,620,000 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.200 | $0.200 | 620,600 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.210 | $0.200 | 818,100 | |
| $0.200 | 0.000 | 0.0% | $0.190 | $0.210 | $0.190 | 1,527,700 | |
| $0.200 | -0.010 | -4.8% | $0.210 | $0.210 | $0.200 | 2,044,400 | |
| $0.210 | +0.010 | +5.0% | $0.210 | $0.210 | $0.200 | 643,700 | |
| $0.200 | -0.020 | -9.1% | $0.210 | $0.230 | $0.200 | 5,316,600 | |
| $0.220 | -0.010 | -4.3% | $0.220 | $0.220 | $0.210 | 1,994,300 | |
| $0.230 | +0.020 | +9.5% | $0.220 | $0.230 | $0.210 | 1,072,200 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.220 | $0.210 | 684,000 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.200 | 542,300 | |
| $0.210 | -0.010 | -4.5% | $0.210 | $0.220 | $0.200 | 723,600 | |
| $0.220 | +0.010 | +4.8% | $0.220 | $0.220 | $0.210 | 1,125,500 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.200 | 900,100 | |
| $0.210 | +0.010 | +5.0% | $0.210 | $0.210 | $0.200 | 3,226,500 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.210 | $0.200 | 1,213,700 | |
| $0.200 | 0.000 | 0.0% | $0.220 | $0.220 | $0.200 | 705,300 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.210 | $0.190 | 1,476,400 | |
| $0.200 | +0.010 | +5.3% | $0.190 | $0.200 | $0.190 | 1,600,900 | |
| $0.190 | -0.010 | -5.0% | $0.200 | $0.200 | $0.180 | 2,408,600 | |
| $0.200 | 0.000 | 0.0% | $0.190 | $0.210 | $0.190 | 1,425,700 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.210 | $0.190 | 2,076,900 | |
| $0.200 | -0.010 | -4.8% | $0.210 | $0.210 | $0.200 | 2,759,500 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.200 | 872,900 | |
| $0.210 | -0.010 | -4.5% | $0.230 | $0.230 | $0.200 | 2,069,800 | |
| $0.220 | -0.020 | -8.3% | $0.220 | $0.240 | $0.210 | 2,691,200 | |
| $0.240 | +0.010 | +4.3% | $0.230 | $0.240 | $0.220 | 816,500 | |
| $0.230 | 0.000 | 0.0% | $0.220 | $0.240 | $0.220 | 938,000 | |
| $0.230 | -0.020 | -8.0% | $0.250 | $0.260 | $0.220 | 1,490,400 | |
| $0.250 | +0.013 | +5.5% | $0.250 | $0.260 | $0.230 | 1,709,800 | |
| $0.237 | +0.020 | +9.3% | $0.220 | $0.249 | $0.217 | 2,419,692 | |
| $0.217 | +0.007 | +3.2% | $0.205 | $0.234 | $0.200 | 1,320,223 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.210 | $0.200 | 803,700 | |
| $0.210 | +0.010 | +5.0% | $0.200 | $0.210 | $0.200 | 1,155,000 |
- Ticker
- OTC:CYDY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
Latest deck · Oct 19, 2026
Corporate Update (October 2026)
Corporate update · 35 slides
Latest news
CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
Nov 17, 2026
Closed $0.25 (-0.3%) on Nov 17, 2026
CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors
Nov 12, 2026
Closed $0.235 (+1.5%) on Nov 12, 2026
CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer
Nov 10, 2026
Closed $0.233 (-2.9%) on Nov 10, 2026
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
Oct 26, 2026
Closed $0.236 (-9.2%) on Oct 26, 2026
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
Oct 19, 2026
Closed $0.25 (0.0%) on Oct 20, 2026
CytoDyn to Host Investor Webcast
Oct 15, 2026
Closed $0.21 (+5.0%) on Oct 15, 2026
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
Oct 8, 2026
Closed $0.20 (0.0%) on Oct 8, 2026
CytoDyn Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in the last 12 months · 7 in all · newest Nov 17, 2026 · oldest 2026
- Decks
- 13 decks · latest Oct 19, 2026
Valuation
Statements: 4 quarters to Aug 31, 2026 · price Nov 20, 2026
- Enterprise value
- $345.8M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.44
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CytoDyn Inc. · OTC:CYDY | US$326.4M | US$345.8M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| Larimar Therapeutics, Inc. · NASDAQ:LRMR | US$328.6M | US$204.7M | n/a | n/a | n/a | 3.2× | n/a | 0.1× | 1.48 |
| C4 Therapeutics, Inc. · NASDAQ:CCCC | US$325.7M | US$175.5M | n/a | 5.4× | n/a | 1.4× | −282.2% | 0.2× | 1.46 |
| Laekna, Inc. · HKEX:2105 | US$322.8M | US$154.7M | n/a | 9.7× | n/a | 1.8× | −214.9% | 0.0× | n/a |
| Foresee Pharmaceuticals Co., Ltd. · TPEX:6576 | US$319.8M | US$303.4M | 469× | 21.2× | n/a | 8.3× | 4.8% | 0.3× | n/a |
| GI Innovation, Inc. · KRX:358570 | US$317.8M | US$288.6M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Atea Pharmaceuticals, Inc. · NASDAQ:AVIR | US$317.6M | US$126.6M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 0.86 |
| MapLight Therapeutics, Inc. · NASDAQ:MPLT | US$313.9M | US$29.84M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.28 |
| Median of the others | US$324.2M | US$200.6M | 469× | 1,151× | 3.4× | 1.8× | −214.9% | 0.1× | 1.37 |
Team and board
Officers
| Officer | Role |
|---|---|
| Robert E. Hoffman | Chief Executive Officer |
| Lauren Wilcoxen | Chief Operating Officer and Head of Regulatory Affairs |
| Tyler Blok | Chief Legal Officer |
| Jacob Lalezari | Head of Research and Translation Sciences |
Board
| Director | Role |
|---|---|
| Tanya Durkee Urbach | Chair |
| Karen J. Brunke | Director |
| Lishomwa C. Ndhlovu | Director |
| Ryan Dunlap | Director |
| Stephen M. Simes | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Oct 28, 2026 | +3.4% |
| Q4 2026 | Jul 29, 2026 | −5.0% |
| Q3 2026 | Apr 29, 2026 | 0.0% |
| Q2 2026 | Jan 28, 2026 | 0.0% |
| Q1 2026 | Sep 2, 2025 · After close | −3.1% |
| Q4 2025 | Jul 30, 2025 | +11.1% |
| Q3 2025 | Apr 14, 2025 · After close | +5.0% |
| Q2 2025 | Jan 14, 2025 · After close | 0.0% |
| Q1 2025 | Oct 15, 2024 · After close | 0.0% |
| Q4 2024 | Aug 15, 2024 · After close | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | Apr 15, 2024 · After close | +7.1% |
| Q2 2024 | Jan 16, 2024 · After close | −5.0% |
| Q1 2024 | Oct 23, 2023 · After close | −5.9% |
| Q4 2023 | Aug 30, 2023 · After close | 0.0% |
| Q3 2023 | Apr 10, 2023 · After close | −6.1% |
| Q2 2023 | Jan 9, 2023 · After close | 0.0% |
| Q1 2023 | Oct 11, 2022 · After close | +9.8% |
| Q4 2022 | Aug 15, 2022 · After close | −4.8% |
| Q3 2022 | Apr 11, 2022 · After close | −3.6% |
| Q2 2022 | Jan 10, 2022 · After close | −20.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (October 2026) | Corporate update | 35 slides | Oct 19, 2026 |
| Investor Presentation (April 2026) | Investor deck | 24 slides | Apr 30, 2026 |
| Technical Presentation (December 2022) | Technical | 100 slides | Dec 7, 2022 |
| Shareholder Meeting (November 2021) | Shareholder meeting | 22 slides | Nov 24, 2021 |
| Proxy Contest (October 2021) | Proxy contest | 13 slides | Oct 4, 2021 |
| Investor Presentation (July 2021) | Investor deck | 23 slides | Jul 22, 2021 |
| Investor Presentation (June 2021) | Investor deck | 19 slides | Jun 21, 2021 |
| Shareholder Meeting (September 2020) | Shareholder meeting | 22 slides | Sep 30, 2020 |
| Biotech Showcase January 2019 | Conference | 20 slides | May 2, 2019 |
| Investor Presentation (January 2019) | Investor deck | 23 slides | Jan 10, 2019 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (November 2018) | Shareholder meeting | 26 slides | Nov 9, 2018 |
| Investor Presentation (March 2018) | Investor deck | 19 slides | Mar 26, 2018 |
| Investor Presentation (March 2017) | Investor deck | 21 slides | Mar 30, 2017 |
Financings
| Raise | Date |
|---|---|
| Private placement of common shares Closed: US$5M raised · US$0.24 a share Use of proceeds: Develop the colorectal cancer program and explore leronlimab in earlier treatment lines and other cancers incl. TNBC, pancreatic cancer, glioblastoma | Nov 12, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 266.0K | 0 | |||||||
| Cost of revenue | 53.0K | |||||||||
| Gross profit | 213.0K | |||||||||
| Research and development | 7.24M | 2.63M | 27.0M | 53.4M | 52.6M | 42.5M | 38.2M | 20.2M | ||
| Operating income | -38.6M | 9.66M | -18.1M | -40.6M | -145.4M | -104.6M | -74.6M | -55.9M | -45.9M | -27.3M |
| Depreciation and amortization | 17.0K | 18.0K | 29.0K | 175.0K | 781.0K | 1.80M | 2.03M | 1.25M | 356.1K | 366.4K |
| EBITDA | -38.6M | 9.68M | -18.0M | -40.4M | -144.6M | -102.8M | -72.6M | -54.6M | -45.6M | -27.0M |
| Interest expense | 18.2M | 3.31M | 5.92M | 612.8K | ||||||
| Income before tax | -42.7M | 3.75M | -49.8M | -79.8M | -210.8M | -176.5M | -139.9M | -63.5M | -50.1M | -25.8M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.83M | 0 | 0 |
| Net income | -42.7M | 3.75M | -49.8M | -79.8M | -210.8M | -176.5M | -139.9M | -60.7M | -50.1M | -25.8M |
| Earnings per share, basic | -0.03 | 0.00 | -0.05 | -0.10 | -0.31 | -0.30 | -0.33 | -0.23 | -0.23 | -0.17 |
| Earnings per share, diluted | -0.03 | 0.00 | -0.05 | -0.10 | -0.31 | -0.30 | -0.33 | -0.23 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 11.9M | 11.9M | 3.11M | 2.54M | 4.23M | 33.9M | 14.3M | 2.61M | 1.23M | 1.78M |
| Inventory | 0 | 0 | 93.5M | 19.1M | ||||||
| Current assets | 13.9M | 17.9M | 10.8M | 10.8M | 10.5M | 36.1M | 36.8M | 5.37M | 3.32M | 6.12M |
| Property, plant and equipment | 73.0K | 134.0K | 55.0K | 29.3K | 11.2K | 17.3K | ||||
| Total assets | 14.0M | 18.0M | 11.1M | 11.3M | 29.2M | 132.1M | 50.5M | 20.9M | 4.90M | 8.06M |
| Accounts payable | 13.2M | 14.7M | 29.6M | 62.7M | 68.0M | 65.9M | 29.5M | 16.2M | 15.8M | 4.28M |
| Current liabilities | 53.7M | 70.5M | 84.2M | 119.8M | 123.2M | 152.5M | 44.5M | 26.9M | 16.7M | 6.14M |
| Total debt | 38.3M | 45.4M | 45.0M | 45.7M | 42.2M | 42.2M | 0 | |||
| Total liabilities | 123.7M | 114.1M | 127.9M | 120.8M | 123.6M | 153.1M | 53.0M | 29.8M | 18.1M | 9.16M |
| Shareholders' equity | -109.7M | -96.0M | -116.8M | -109.5M | -94.4M | -21.0M | -2.48M | -8.91M | -13.2M | -1.10M |
| Shares outstanding | 1.37B | 1.25B | 1.06B | 918.6M | 719.6M | 625.7M | 519.0M | 329.4M | 216.7M | 149.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -17.3M | -8.77M | -11.0M | -25.1M | -77.7M | -117.6M | -68.8M | -50.5M | -29.9M | -26.7M |
| Capital spending | -122.0K | -41.0K | -26.0K | 0 | -11.1K | |||||
| Free cash flow | -117.7M | -68.8M | -50.5M | -29.9M | -26.7M | |||||
| Cash from investing | 0 | 0 | -122.0K | -41.0K | -45.0K | 0 | -11.1K | |||
| Cash from financing | 17.2M | 10.9M | 11.7M | 29.9M | 48.0M | 137.3M | 79.7M | 52.7M | 29.4M | 18.9M |
| Change in cash | -51.0K | 2.09M | 766.0K | 4.82M | -29.7M | 19.7M | 10.8M | 2.24M | -544.1K | -7.87M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Nov 17, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Oct 19, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 19, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Oct 14, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Oct 8, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 7, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 5, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 5, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEF 14A · Proxy statement | Sep 28, 2026 | Meeting notice | SEC |
| S-3 · Registration statement | Sep 25, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Sep 25, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Sep 25, 2026 | Offer document | SEC |
| 10-K · Annual report | Aug 31, 2026 | Annual report | SEC |
| EFFECT · Notice that a registration is effective | May 21, 2026 | Other filings | SEC |
| 424B3 · Prospectus | May 20, 2026 | Offer document | SEC |
| D | May 8, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| S-1 · Registration statement | Apr 22, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 8, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Apr 8, 2026 | Quarterly report | SEC |
| 424B3 · Prospectus | Mar 25, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 24, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Mar 9, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 5, 2026 | Financing | SEC |
| 424B3 · Prospectus | Jan 9, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Jan 9, 2026 | Quarterly report | SEC |
| 424B3 · Prospectus | Dec 22, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 17, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Dec 10, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 3, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 2, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 1, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Nov 26, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 21, 2025 | Meeting outcome | SEC |
| S-3 · Registration statement | Nov 4, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Nov 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 3, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Oct 10, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Sep 30, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Sep 29, 2025 | Offer document | SEC |
| DEF 14A · Proxy statement | Sep 29, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 19, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 19, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 31, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Jul 25, 2025 | Annual report | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 22, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | May 16, 2025 | Offer document | SEC |
| 8-K · Current report | May 16, 2025 | Current report | SEC |
| 424B3 · Prospectus | May 6, 2025 | Offer document | SEC |
| 8-K · Current report | May 6, 2025 | Management or board change | SEC |
| 424B3 · Prospectus | Apr 15, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Apr 14, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | Jan 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Jan 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 22, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Oct 17, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 15, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Oct 11, 2024 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Oct 2, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Oct 1, 2024 | Offer document | SEC |
| 10-K/A · Annual report, amended | Sep 30, 2024 | Annual report | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 17, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 13, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 13, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Sep 6, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Sep 6, 2024 | Offer document | SEC |
| S-1 · Registration statement | Sep 6, 2024 | Offer document | SEC |
| 10-K · Annual report | Aug 15, 2024 | Annual report | SEC |
| SC TO-I/A | Jul 22, 2024 | Acquisition or disposal | SEC |
| 424B3 · Prospectus | Jul 9, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Jul 9, 2024 | Offer document | SEC |
| SC TO-I/A | Jul 9, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Jul 9, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Jun 28, 2024 | Other filings | SEC |
| SC TO-I/A | Jun 28, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 28, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Jun 20, 2024 | Other filings | SEC |
| SC TO-I/A | Jun 20, 2024 | Acquisition or disposal | SEC |
| CORRESP · Letter to the SEC | Jun 12, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 10, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 3, 2024 | Financing | SEC |
| SC TO-I | Jun 3, 2024 | Acquisition or disposal | SEC |
| 424B3 · Prospectus | May 6, 2024 | Offer document | SEC |
| 424B3 · Prospectus | May 6, 2024 | Offer document | SEC |
| 8-K · Current report | May 6, 2024 | Current report | SEC |
| 424B3 · Prospectus | Apr 16, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Apr 16, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Apr 15, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | Apr 8, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Apr 8, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 8, 2024 | Current report | SEC |
| 8-K · Current report | Mar 28, 2024 | Financing | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Mar 1, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Mar 1, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Feb 22, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 22, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 15, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Feb 15, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 13, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| S-1 · Registration statement | Feb 6, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Jan 29, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 29, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | Jan 19, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Jan 16, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 22, 2023 | Current report | SEC |
| 424B3 · Prospectus | Dec 15, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 14, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Nov 29, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 28, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 28, 2023 | Current report | SEC |
| 424B3 · Prospectus | Nov 22, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 21, 2023 | Management or board change | SEC |
| 424B3 · Prospectus | Nov 13, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 9, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Nov 3, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Nov 3, 2023 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Oct 25, 2023 | Big-stake notice | SEC |
| 424B3 · Prospectus | Oct 24, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 23, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Oct 16, 2023 | Explanation request | SEC |
| 424B3 · Prospectus | Oct 10, 2023 | Offer document | SEC |
| DEFA14A · Additional proxy material | Oct 10, 2023 | Meeting notice | SEC |
| 8-K · Current report | Oct 10, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 6, 2023 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Oct 2, 2023 | Offer document | SEC |
| DEFA14A · Additional proxy material | Sep 27, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 25, 2023 | Meeting notice | SEC |
| 8-K · Current report | Sep 25, 2023 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Sep 15, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Sep 13, 2023 | Annual report | SEC |
| NT 10-K · Late filing notice | Aug 30, 2023 | Explanation request | SEC |
| 3 · Initial statement of ownership | Aug 25, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 17, 2023 | Financing | SEC |
| 424B3 · Prospectus | Jul 11, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 11, 2023 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jul 11, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 6, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 26, 2023 | Other filings | SEC |
| S-1 · Registration statement | Jun 21, 2023 | Offer document | SEC |
| 8-K · Current report | May 24, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Apr 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Mar 8, 2023 | Financing | SEC |
| 8-K · Current report | Mar 2, 2023 | Financing | SEC |
| 4 · Change in ownership | Feb 14, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2023 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Feb 3, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Feb 3, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Feb 3, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Feb 3, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Feb 3, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Feb 3, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Feb 3, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Feb 3, 2023 | Offer document | SEC |
| 8-K · Current report | Feb 1, 2023 | Financing | SEC |
| 10-Q · Quarterly report | Jan 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Dec 19, 2022 | Management or board change | SEC |
| 8-K · Current report | Dec 9, 2022 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Dec 7, 2022 | Meeting notice | SEC |
| 8-K · Current report | Dec 7, 2022 | Current report | SEC |
| DEFA14A · Additional proxy material | Dec 6, 2022 | Meeting notice | SEC |
| 8-K · Current report | Dec 6, 2022 | Material contract | SEC |
| 4 · Change in ownership | Nov 30, 2022 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from CytoDyn Inc.’s releases · as of Nov 12, 2026
- Common shares
- 1,469,518,019
- Fully diluted
- 1,469,518,019
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,469,518,019 | Nov 12, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,469,518,019 |
| Nov 12, 2026 | 1,394,350,333 |
| May 31, 2026 | 1,373,517,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert E. Hoffman Other companies: Esperion Therapeutics, Inc. (Director · Since at least Apr 1, 2025); FibroBiologics, Inc. (Director · Since at least Jan 24, 2024); TuHURA Biosciences, Inc. (Director · Since at least Apr 11, 2018); Aravive Inc (Director · Oct 12, 2018 – Sep 12, 2019 · Past); Heron Therapeutics, Inc. (CFO & SVP, Finance · Apr 24, 2017 – Dec 19, 2019 · Past); Kura Oncology, Inc. (Director · May 12, 2016 – Jun 22, 2021 · Past); CombiMatrix Corp (Director · May 10, 2016 – Nov 14, 2017 · Past); MabVax Therapeutics Holdings Inc (Director · Aug 26, 2015 – May 19, 2017 · Past) | Chief Financial Officer · Since at least May 15, 2025 |
| Alan Bruce Montgomery Other companies: Xencor, Inc. (Director · Since at least Jun 23, 2016); Alder BioPharmaceuticals Inc (Director · May 26, 2016 – Oct 22, 2019 · Past) | Director · Jun 1, 2016 – Jul 12, 2018 · Past |
| Alan P Timmins | Director · Jan 18, 2020 – Nov 24, 2021 · Past |
| Antonio Migliarese | CFO · Mar 31, 2022 – Jan 3, 2024 · Past |
| Arian Colachis | GC and Corporate Secretary · Mar 16, 2020 – Oct 23, 2020 · Past |
| Arvin Cyrus Arman | President · Jul 9, 2022 – Feb 13, 2023 · Past |
| Chris P Recknor | See Remarks · Mar 31, 2022 – Mar 31, 2022 · Past |
| Gordon A Gardiner | Director · Jul 1, 2021 – Nov 24, 2021 · Past |
| Jacob Lalezari | Chief Executive Officer · Since at least Nov 17, 2023 |
| Karen J. Brunke | Director · Since at least Mar 30, 2022 |
All 18 people
| Person | Seat |
|---|---|
| Lauren Wilcoxen | Chief Operating Officer and Head of Regulatory Affairs · Since Nov 17, 2026 |
| Lishomwa C. Ndhlovu | Director · Since at least Nov 24, 2021 |
| Michael A Klump | Director · May 8, 2019 – Dec 19, 2019 · Past |
| Nader Pourhassan | President & CEO, Director · May 31, 2011 – Oct 18, 2021 · Past |
| Ryan Dunlap | Director · Since at least Mar 20, 2026 |
| Stephen M. Simes | Director · Since at least Nov 18, 2026 |
| Tanya Durkee Urbach | Director · Since at least Jan 3, 2024 |
| Tyler Blok | Chief Legal Officer · Since at least Aug 15, 2023 |
Log in to ask 6ix AI your own questions about CytoDyn Inc.